ArticleFrontiers in oncology2025
AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors. Most patients are diagnosed at advanced or metastatic stages, losing the opportunity for curative surgery. Current systemic treatments for pancreatic cancer remain suboptimal. Case summary: A 68-year-old female presented with upper abdominal pain. Imaging revealed a pancreatic mass, prompting an exploratory laparotomy. Intraoperative frozen section pathology identified metastatic adenocarcinoma nodules near the hepatic artery. The patient was subsequently evaluated and enrolled in a clinical trial. The treatment regimen comprised AG chemotherapy (nab-paclitaxel and gemcitabine) combined with AK112 (a novel bispecific antibody). After 13 administrations of AG chemotherapy and 9 infusions of AK112, imaging evaluation demonstrated partial tumor regression. A multidisciplinary team (MDT) assessment deemed the lesion potentially resec]. The exploratory laparotomy confirmed resectability, and a total pancreatectomy was performed. Postoperative pathology confirmed moderately differentiated pancreatic ductal adenocarcinoma with focal degenerative changes. During postoperative treatment, wound exudate suggestive of intestinal leakage prompted surgical intervention on June 12, 2023. Adjuvant therapy resumed after wound healing but was discontinued in September 2023 due to recurrent incision leakage. Maintenance therapy with tegafur was initiated thereafter. Unfortunately, the patient died of acute myocardial infarction on August 4, 2024. Conclusion: The combination therapy of AK112 and AG achieved good results in this case, but the broader efficacy of this regimen across the pancreatic cancer population awaits validation through large-scale clinical trials. The ongoing trials are highly anticipated, as successful results could establish AK112 as a novel therapeutic strategy for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.